Key Points
- Guardant Health director Medina Manuel Hidalgo sold 1,700 shares for $279,208 at an average price of $164.24, reducing his direct stake by 27.17% to 4,556 shares.
- GH shares opened at $157.58 and remain near their 52-week high of $176.58, with a $21.15 billion market capitalization; institutional investors own 92.6% of the stock.
- Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $183.78, while several firms recently raised targets to between $180 and $210.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Medina Manuel Hidalgo sold 1,700 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $164.24, for a total value of $279,208.00. Following the completion of the sale, the director directly owned 4,556 shares in the company, valued at $748,277.44. This represents a 27.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Medina Manuel Hidalgo also recently made the following trade(s):
- On Thursday, May 28th, Medina Manuel Hidalgo sold 1,000 shares of Guardant Health stock. The shares were sold at an average price of $130.06, for a total value of $130,060.00.
- On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The stock was sold at an average price of $107.09, for a total value of $133,862.50.
Guardant Health Stock Performance
GH stock opened at $157.58 on Friday. The company's 50 day moving average price is $146.24 and its 200 day moving average price is $114.82. Guardant Health, Inc. has a fifty-two week low of $48.25 and a fifty-two week high of $176.58. The firm has a market capitalization of $21.15 billion, a price-to-earnings ratio of -45.15 and a beta of 1.60.
Institutional Trading of Guardant Health
Several institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in shares of Guardant Health by 14.5% during the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company's stock worth $145,000 after purchasing an additional 122 shares during the period. First Pacific Financial increased its stake in Guardant Health by 33.1% in the first quarter. First Pacific Financial now owns 559 shares of the company's stock valued at $52,000 after purchasing an additional 139 shares during the last quarter. Xponance LLC increased its stake in Guardant Health by 2.1% in the fourth quarter. Xponance LLC now owns 9,630 shares of the company's stock valued at $984,000 after purchasing an additional 199 shares during the last quarter. Danske Bank A S lifted its position in Guardant Health by 20.0% during the fourth quarter. Danske Bank A S now owns 1,200 shares of the company's stock worth $123,000 after buying an additional 200 shares during the period. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna boosted its stake in Guardant Health by 1.9% in the 4th quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company's stock worth $1,124,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the stock. Guggenheim increased their price objective on shares of Guardant Health from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 16th. The Goldman Sachs Group reiterated a "buy" rating and set a $210.00 target price on shares of Guardant Health in a research note on Friday, July 31st. Stifel Nicolaus increased their target price on Guardant Health from $130.00 to $180.00 and gave the company a "buy" rating in a report on Friday, July 31st. BTIG Research raised their price target on Guardant Health from $190.00 to $195.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Finally, Bank of America upped their price objective on Guardant Health from $135.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $183.78.
Read Our Latest Stock Report on GH
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
